DermTech (DMTK) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
DermTech Reports Third Quarter 2020 Financial Results
November 10, 2020 4:01 PM ESTLA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results as of and for the quarter ended September 30, 2020.
Third Quarter Highlights
Assay revenues of $1.2 million for the third quarter of 2020, a 220% increase compared to the third quarter of 2019 and a 90% sequential increase over the second quarter of 2020. Billable sample volume of approximately 6,700 for the third quarter of 2020, an 86% increase compared to approximately 3,600 recorded for the third quarter of 2019 and a... More


